Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression
Case ID:
TAB-3583
Web Published:
12/6/2022
This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic effects. The downstream metabolite, (2R,6R)-HNK, does not inhibit the NMDA receptor but recapitulates the antidepressant and anti-suicidal effect of ketamine. Further clinical work could establish a ketamine metabolite, such as (2R,6R)-HNK, for the treatment of depression.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech?title=Use_of_the_Ketamine_Me tabolite_(R%2c6R)-hydroxynorketamine_in_Depression
Keywords:
2R
6R-hydroxynorketamine
depression
Ketamine
METABOLITE
VEXXXX
VNXXXX
WIXXXX
WKXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Suryanarayana Vepa
Deputy Director; OSA
NIH Technology Transfer
301-827-7181
sury.vepa@nih.gov